mortality/aging
• almost all mutants die by 18 months of age
(J:74377)
• some mutants die with renal disease
(J:74377)
• while many mutants die around 8 to 9 months of age from severe systemic AA amyloidosis, some mutants develop amyloidosis by 3-5 months of age and die sooner
(J:177820)
|
neoplasm
• 29% of mutants develop B cell lymphomas
• mutants with B cell lymphoma include cases of follicular B cell lymphoma and diffuse large-cell B cell lymphoma
|
• mutants begin to develop plasmacytoma at 6 months of age such that 56% of mutants have plasmacytoma in the lymph nodes, Peyer's patches and/or spleen by 18 months of age
• mice that develop B cell lymphomas also develop plasmacytoma, often in the form of multicentric microplasmacytoma
• 16% of mutants remain tumor free but are at the transitional stage between plasma cell hyperplasia, multicentric microplasmacytoma and plasmacytoma
• tumors are of three subtypes, either a typical mature plasmacytic form, a less mature plasmacytoid or plasmablastic form, or highly aggressive anaplastic form
• mice with anaplastic or plasmablastic plasmacytoma do not exhibit M-components in the serum
• plasmacytomas and some lymphomas are characterized by Myc-activating T(12;15) chromosomal translocations, but do not express IgA
|
immune system
• amyloid deposits cause irregular thickening of the arterial walls within the splenic trabeculae
|
• due to amyloid deposits and probably also follicular lymphoid hyperplasia and plasmacytosis
• amyloid deposits distort the normal splenic architecture, separating the trabeculae and periarteriolar lymphoid sheaths and expanding the extracellular matrix of the reticular fiber network of the sinusoids
|
• amyloid deposits cause irregular thickening of the venous walls within the splenic trabeculae
|
• mutants without lymphoid neoplasia exhibit an increase in serum polyclonal Ig levels, specifically IgG1 and IgG2b, and the presence of M-components
|
behavior/neurological
• fail to groom adequately
|
• hunched resting posture
|
hematopoietic system
• amyloid deposits cause irregular thickening of the arterial walls within the splenic trabeculae
|
• due to amyloid deposits and probably also follicular lymphoid hyperplasia and plasmacytosis
• amyloid deposits distort the normal splenic architecture, separating the trabeculae and periarteriolar lymphoid sheaths and expanding the extracellular matrix of the reticular fiber network of the sinusoids
|
• amyloid deposits cause irregular thickening of the venous walls within the splenic trabeculae
|
• mutants without lymphoid neoplasia exhibit an increase in serum polyclonal Ig levels, specifically IgG1 and IgG2b, and the presence of M-components
|
cardiovascular system
• amyloid deposits cause irregular thickening of the arterial walls within the splenic trabeculae
|
homeostasis/metabolism
amyloidosis
(
J:177820
)
• mutants develop spontaneous amyloid protein A (AA) amyloidosis which begins with splenic deposits of AA at 5 months of age and progresses to deposits in the liver, kidney, and vasculature
• however, several mutants develop severe amyloidosis as early as 3 to 5 months of age
|
growth/size/body
• due to amyloid deposits and probably also follicular lymphoid hyperplasia and plasmacytosis
• amyloid deposits distort the normal splenic architecture, separating the trabeculae and periarteriolar lymphoid sheaths and expanding the extracellular matrix of the reticular fiber network of the sinusoids
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
amyloidosis | DOID:9120 | J:177820 | ||
plasmacytoma | DOID:3721 | J:74377 |